Branford, Connecticut, United States, November 10, 2026
Azitra, Inc., a clinical-stage biotechnology company focused on precision dermatology and innovative skincare technologies, has announced new research findings for its investigational cosmetic candidate ATR-COSF, demonstrating improvements in the appearance of fine lines, wrinkles and skin elasticity in ex vivo human skin models. The company presented the research at the BIO-Europe 2026 conference in Cologne, Germany, on November 10, highlighting the potential of recombinant filaggrin protein technology for topical cosmetic applications. ATR-COSF is designed to deliver functional domains of human filaggrin into the skin through a topical formulation. According to the company, a single application produced a 56% reduction in wrinkles from baseline in one ex vivo human skin model, alongside improvements in skin elasticity and wrinkle depth compared with the vehicle formulation. Azitra also announced that initial results from its planned first-in-human study are anticipated by the end of 2026. The findings represent an important research milestone in the development of biotechnology-based skincare products targeting visible signs of skin ageing.
ATR-COSF Demonstrates Improvements in Human Skin Models
The ATR-COSF research program focuses on using recombinant human filaggrin protein domains to improve skin appearance and support skin barrier-related functions. Filaggrin is a naturally occurring structural protein that plays an important role in maintaining the skin barrier and supporting skin hydration. Azitra’s technology uses a genetically engineered strain of Staphylococcus epidermidis to produce and secrete a functional human filaggrin protein domain. The resulting supernatant is incorporated into a topical hydrogel formulation for cosmetic applications. In the research presented at BIO-Europe, investigators evaluated ATR-COSF using ex vivo human skin samples obtained from cosmetic surgical procedures. The company reported that a single topical application produced a 56% reduction in wrinkle measurements from baseline in an ex vivo human torso skin model. Additional assessments indicated improvements in wrinkle depth and skin elasticity compared with the vehicle control after 48 hours. These findings suggest that the recombinant protein-based formulation may have potential for reducing visible signs of skin ageing. However, the research was conducted using human skin tissue outside the living body, and the findings should not be interpreted as demonstrated clinical benefits in consumers.
Recombinant Filaggrin Technology Supports Cosmetic Innovation
The development of ATR-COSF highlights the growing application of biotechnology and engineered proteins in cosmetic research. Traditional skincare formulations frequently use moisturizing ingredients, peptides and other compounds to improve skin appearance. Azitra is investigating a different approach by using recombinant human filaggrin domains as an active ingredient in a topical cosmetic formulation. The company’s proprietary microbial engineering platform enables the production of selected human protein components through an engineered bacterial strain. The formulation is designed to deliver these functional protein domains to the skin surface. According to Azitra, the ex vivo findings showed improvements across multiple skin measurements, including visible wrinkle appearance, wrinkle depth and elasticity. The company believes this approach could support the development of differentiated skincare products targeting fine lines and wrinkles. The research also demonstrates how technologies initially developed for dermatological therapeutic applications can potentially be adapted for cosmetic and cosmeceutical development. Nevertheless, further investigation will be required to establish the formulation’s performance, safety, stability and effectiveness in human users under normal skincare conditions.
Advertisement
First-in-Human Study Expected to Advance Development
Following the encouraging ex vivo findings, Azitra is preparing to advance the 4% ATR-COSF formulation into a first-in-human study involving approximately 30 participants. The company expects initial results from the study by the end of 2026. This investigation is intended to provide early information about the topical formulation’s performance and help determine whether the improvements observed in laboratory skin models can be reproduced in people. The planned study represents an important transition from preclinical research to human evaluation. Azitra’s broader biotechnology portfolio also includes ATR-04, an investigational live biotherapeutic being studied for skin rashes associated with certain cancer treatments. The company’s research strategy combines microbial engineering, recombinant proteins, topical biological products and precision dermatology approaches. Travis Whitfill, PhD, MPH, Co-founder and Chief Operating Officer of Azitra, highlighted the importance of the ATR-COSF findings and their potential to guide the development of a filaggrin-based topical cosmetic product. The company also plans to use its BIO-Europe participation to discuss research progress and potential development partnerships. ATR-COSF remains an investigational cosmetic candidate, and its potential benefits will need to be evaluated through further human studies before its performance in consumers can be established. Overall, Azitra’s ATR-COSF research represents an interesting development in biotechnology-driven cosmetic innovation and anti-ageing skincare research. The reported improvements in wrinkle appearance and skin elasticity provide a scientific basis for advancing the formulation into human evaluation. If future studies confirm these findings, recombinant filaggrin technology could offer a differentiated approach to cosmetic skincare development. The upcoming first-in-human results will be an important milestone in determining the candidate’s potential for future cosmetic applications.
Source: Azitra Inc press release
